Skip to main content
PMC home page
Molecular and Cellular Biology logoLink to Molecular and Cellular Biology
. 1997 Jun;17(6):3229–3241. doi: 10.1128/mcb.17.6.3229

Inhibition of the Raf-1 kinase by cyclic AMP agonists causes apoptosis of v-abl-transformed cells.

E M Weissinger 1, G Eissner 1, C Grammer 1, S Fackler 1, B Haefner 1, L S Yoon 1, K S Lu 1, A Bazarov 1, J M Sedivy 1, H Mischak 1, W Kolch 1
PMCID: PMC232176  PMID: 9154822

Abstract

Here we investigate the role of the Raf-1 kinase in transformation by the v-abl oncogene. Raf-1 can activate a transforming signalling cascade comprising the consecutive activation of Mek and extracellular-signal-regulated kinases (Erks). In v-abl-transformed cells the endogenous Raf-1 protein was phosphorylated on tyrosine and displayed high constitutive kinase activity. The activities of the Erks were constitutively elevated in both v-raf- and v-abl-transformed cells. In both cell types the activities of Raf-1 and v-raf were almost completely suppressed after activation of the cyclic AMP-dependent kinase (protein kinase A [PKA]), whereas the v-abl kinase was not affected. Raf inhibition substantially diminished the activities of Erks in v-raf-transformed cells but not in v-abl-transformed cells, indicating that v-abl can activate Erks by a Raf-1-independent pathway. PKA activation induced apoptosis in v-abl-transformed cells while reverting v-raf transformation without severe cytopathic effects. Overexpression of Raf-1 in v-abl-transformed cells partially protected the cells from apoptosis induced by PKA activation. In contrast to PKA activators, a Mek inhibitor did not induce apoptosis. The diverse biological responses correlated with the status of c-myc gene expression. v-abl-transformed cells featured high constitutive levels of expression of c-myc, which were not reduced following PKA activation. Myc activation has been previously shown to be essential for transformation by oncogenic Abl proteins. Using estrogen-regulated c-myc and temperature-sensitive Raf-1 mutants, we found that Raf-1 activation could protect cells from c-myc-induced apoptosis. In conclusion, these results suggest (i) that Raf-1 participates in v-abl transformation via an Erk-independent pathway by providing a survival signal which complements c-myc in transformation, and (ii) that cAMP agonists might become useful for the treatment of malignancies where abl oncogenes are involved, such as chronic myeloid leukemias.

Full Text

The Full Text of this article is available as a PDF (1.5 MB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ally S., Clair T., Katsaros D., Tortora G., Yokozaki H., Finch R. A., Avery T. L., Cho-Chung Y. S. Inhibition of growth and modulation of gene expression in human lung carcinoma in athymic mice by site-selective 8-Cl-cyclic adenosine monophosphate. Cancer Res. 1989 Oct 15;49(20):5650–5655. [PubMed] [Google Scholar]
  2. Arcinas M., Sizer K. C., Boxer L. M. Activation of c-myc expression by c-Abl is independent of both the DNA binding function of c-Abl and the c-myc EP site. J Biol Chem. 1994 Aug 26;269(34):21919–21924. [PubMed] [Google Scholar]
  3. Bagrodia S., Taylor S. J., Shalloway D. Myristylation is required for Tyr-527 dephosphorylation and activation of pp60c-src in mitosis. Mol Cell Biol. 1993 Mar;13(3):1464–1470. doi: 10.1128/mcb.13.3.1464. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Burgering B. M., Pronk G. J., van Weeren P. C., Chardin P., Bos J. L. cAMP antagonizes p21ras-directed activation of extracellular signal-regulated kinase 2 and phosphorylation of mSos nucleotide exchange factor. EMBO J. 1993 Nov;12(11):4211–4220. doi: 10.1002/j.1460-2075.1993.tb06105.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Büscher D., Hipskind R. A., Krautwald S., Reimann T., Baccarini M. Ras-dependent and -independent pathways target the mitogen-activated protein kinase network in macrophages. Mol Cell Biol. 1995 Jan;15(1):466–475. doi: 10.1128/mcb.15.1.466. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Carroll M. P., May W. S. Protein kinase C-mediated serine phosphorylation directly activates Raf-1 in murine hematopoietic cells. J Biol Chem. 1994 Jan 14;269(2):1249–1256. [PubMed] [Google Scholar]
  7. Chapman R. S., Whetton A. D., Dive C. The suppression of drug-induced apoptosis by activation of v-ABL protein tyrosine kinase. Cancer Res. 1994 Oct 1;54(19):5131–5137. [PubMed] [Google Scholar]
  8. Cleveland J. L., Dean M., Rosenberg N., Wang J. Y., Rapp U. R. Tyrosine kinase oncogenes abrogate interleukin-3 dependence of murine myeloid cells through signaling pathways involving c-myc: conditional regulation of c-myc transcription by temperature-sensitive v-abl. Mol Cell Biol. 1989 Dec;9(12):5685–5695. doi: 10.1128/mcb.9.12.5685. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Cleveland J. L., Jansen H. W., Bister K., Fredrickson T. N., Morse H. C., 3rd, Ihle J. N., Rapp U. R. Interaction between Raf and Myc oncogenes in transformation in vivo and in vitro. J Cell Biochem. 1986;30(3):195–218. doi: 10.1002/jcb.240300303. [DOI] [PubMed] [Google Scholar]
  10. Cleveland J. L., Troppmair J., Packham G., Askew D. S., Lloyd P., González-Garcia M., Nuñez G., Ihle J. N., Rapp U. R. v-raf suppresses apoptosis and promotes growth of interleukin-3-dependent myeloid cells. Oncogene. 1994 Aug;9(8):2217–2226. [PubMed] [Google Scholar]
  11. Cook S. J., McCormick F. Inhibition by cAMP of Ras-dependent activation of Raf. Science. 1993 Nov 12;262(5136):1069–1072. doi: 10.1126/science.7694367. [DOI] [PubMed] [Google Scholar]
  12. Cortez D., Kadlec L., Pendergast A. M. Structural and signaling requirements for BCR-ABL-mediated transformation and inhibition of apoptosis. Mol Cell Biol. 1995 Oct;15(10):5531–5541. doi: 10.1128/mcb.15.10.5531. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Cotter T. G., Lennon S. V., Glynn J. M., Green D. R. Microfilament-disrupting agents prevent the formation of apoptotic bodies in tumor cells undergoing apoptosis. Cancer Res. 1992 Feb 15;52(4):997–1005. [PubMed] [Google Scholar]
  14. Cowley S., Paterson H., Kemp P., Marshall C. J. Activation of MAP kinase kinase is necessary and sufficient for PC12 differentiation and for transformation of NIH 3T3 cells. Cell. 1994 Jun 17;77(6):841–852. doi: 10.1016/0092-8674(94)90133-3. [DOI] [PubMed] [Google Scholar]
  15. Cruz-Reyes J., Tata J. R. Cloning, characterization and expression of two Xenopus bcl-2-like cell-survival genes. Gene. 1995 Jun 9;158(2):171–179. doi: 10.1016/0378-1119(95)00159-4. [DOI] [PubMed] [Google Scholar]
  16. Curran T., Franza B. R., Jr Fos and Jun: the AP-1 connection. Cell. 1988 Nov 4;55(3):395–397. doi: 10.1016/0092-8674(88)90024-4. [DOI] [PubMed] [Google Scholar]
  17. Darzynkiewicz Z., Bruno S., Del Bino G., Gorczyca W., Hotz M. A., Lassota P., Traganos F. Features of apoptotic cells measured by flow cytometry. Cytometry. 1992;13(8):795–808. doi: 10.1002/cyto.990130802. [DOI] [PubMed] [Google Scholar]
  18. Daum G., Eisenmann-Tappe I., Fries H. W., Troppmair J., Rapp U. R. The ins and outs of Raf kinases. Trends Biochem Sci. 1994 Nov;19(11):474–480. doi: 10.1016/0968-0004(94)90133-3. [DOI] [PubMed] [Google Scholar]
  19. Dudley D. T., Pang L., Decker S. J., Bridges A. J., Saltiel A. R. A synthetic inhibitor of the mitogen-activated protein kinase cascade. Proc Natl Acad Sci U S A. 1995 Aug 15;92(17):7686–7689. doi: 10.1073/pnas.92.17.7686. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Durkin J. P., Whitfield J. F. The viral Ki-ras gene must be expressed in the G2 phase if ts Kirsten sarcoma virus-infected NRK cells are to proliferate in serum-free medium. Mol Cell Biol. 1987 Jan;7(1):444–449. doi: 10.1128/mcb.7.1.444. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Eilers M., Picard D., Yamamoto K. R., Bishop J. M. Chimaeras of myc oncoprotein and steroid receptors cause hormone-dependent transformation of cells. Nature. 1989 Jul 6;340(6228):66–68. doi: 10.1038/340066a0. [DOI] [PubMed] [Google Scholar]
  22. Eissner G., Kohlhuber F., Grell M., Ueffing M., Scheurich P., Hieke A., Multhoff G., Bornkamm G. W., Holler E. Critical involvement of transmembrane tumor necrosis factor-alpha in endothelial programmed cell death mediated by ionizing radiation and bacterial endotoxin. Blood. 1995 Dec 1;86(11):4184–4193. [PubMed] [Google Scholar]
  23. Evan G. I., Littlewood T. D. The role of c-myc in cell growth. Curr Opin Genet Dev. 1993 Feb;3(1):44–49. doi: 10.1016/s0959-437x(05)80339-9. [DOI] [PubMed] [Google Scholar]
  24. Evan G. I., Wyllie A. H., Gilbert C. S., Littlewood T. D., Land H., Brooks M., Waters C. M., Penn L. Z., Hancock D. C. Induction of apoptosis in fibroblasts by c-myc protein. Cell. 1992 Apr 3;69(1):119–128. doi: 10.1016/0092-8674(92)90123-t. [DOI] [PubMed] [Google Scholar]
  25. Evans C. A., Owen-Lynch P. J., Whetton A. D., Dive C. Activation of the Abelson tyrosine kinase activity is associated with suppression of apoptosis in hemopoietic cells. Cancer Res. 1993 Apr 15;53(8):1735–1738. [PubMed] [Google Scholar]
  26. Fabian J. R., Daar I. O., Morrison D. K. Critical tyrosine residues regulate the enzymatic and biological activity of Raf-1 kinase. Mol Cell Biol. 1993 Nov;13(11):7170–7179. doi: 10.1128/mcb.13.11.7170. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Feig L. A., Schaffhausen B. Signal transduction. The hunt for Ras targets. Nature. 1994 Aug 18;370(6490):508–509. doi: 10.1038/370508a0. [DOI] [PubMed] [Google Scholar]
  28. Feller S. M., Knudsen B., Hanafusa H. Cellular proteins binding to the first Src homology 3 (SH3) domain of the proto-oncogene product c-Crk indicate Crk-specific signaling pathways. Oncogene. 1995 Apr 20;10(8):1465–1473. [PubMed] [Google Scholar]
  29. Feller S. M., Knudsen B., Hanafusa H. c-Abl kinase regulates the protein binding activity of c-Crk. EMBO J. 1994 May 15;13(10):2341–2351. doi: 10.1002/j.1460-2075.1994.tb06518.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Fraker P. J., King L. E., Lill-Elghanian D., Telford W. G. Quantification of apoptotic events in pure and heterogeneous populations of cells using the flow cytometer. Methods Cell Biol. 1995;46:57–76. doi: 10.1016/s0091-679x(08)61924-x. [DOI] [PubMed] [Google Scholar]
  31. Fujita M., Shiku H. Differences in sensitivity to induction of apoptosis among rat fibroblast cells transformed by HTLV-I tax gene or cellular nuclear oncogenes. Oncogene. 1995 Jul 6;11(1):15–20. [PubMed] [Google Scholar]
  32. Fumagalli S., Totty N. F., Hsuan J. J., Courtneidge S. A. A target for Src in mitosis. Nature. 1994 Apr 28;368(6474):871–874. doi: 10.1038/368871a0. [DOI] [PubMed] [Google Scholar]
  33. Gardner A. M., Vaillancourt R. R., Johnson G. L. Activation of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase by G protein and tyrosine kinase oncoproteins. J Biol Chem. 1993 Aug 25;268(24):17896–17901. [PubMed] [Google Scholar]
  34. Gille H., Sharrocks A. D., Shaw P. E. Phosphorylation of transcription factor p62TCF by MAP kinase stimulates ternary complex formation at c-fos promoter. Nature. 1992 Jul 30;358(6385):414–417. doi: 10.1038/358414a0. [DOI] [PubMed] [Google Scholar]
  35. Goga A., McLaughlin J., Afar D. E., Saffran D. C., Witte O. N. Alternative signals to RAS for hematopoietic transformation by the BCR-ABL oncogene. Cell. 1995 Sep 22;82(6):981–988. doi: 10.1016/0092-8674(95)90277-5. [DOI] [PubMed] [Google Scholar]
  36. Graves L. M., Bornfeldt K. E., Raines E. W., Potts B. C., Macdonald S. G., Ross R., Krebs E. G. Protein kinase A antagonizes platelet-derived growth factor-induced signaling by mitogen-activated protein kinase in human arterial smooth muscle cells. Proc Natl Acad Sci U S A. 1993 Nov 1;90(21):10300–10304. doi: 10.1073/pnas.90.21.10300. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Green D. R., Mahboubi A., Nishioka W., Oja S., Echeverri F., Shi Y., Glynn J., Yang Y., Ashwell J., Bissonnette R. Promotion and inhibition of activation-induced apoptosis in T-cell hybridomas by oncogenes and related signals. Immunol Rev. 1994 Dec;142:321–342. doi: 10.1111/j.1600-065x.1994.tb00895.x. [DOI] [PubMed] [Google Scholar]
  38. Heidecker G., Huleihel M., Cleveland J. L., Kolch W., Beck T. W., Lloyd P., Pawson T., Rapp U. R. Mutational activation of c-raf-1 and definition of the minimal transforming sequence. Mol Cell Biol. 1990 Jun;10(6):2503–2512. doi: 10.1128/mcb.10.6.2503. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Hordijk P. L., Verlaan I., Jalink K., van Corven E. J., Moolenaar W. H. cAMP abrogates the p21ras-mitogen-activated protein kinase pathway in fibroblasts. J Biol Chem. 1994 Feb 4;269(5):3534–3538. [PubMed] [Google Scholar]
  40. Häfner S., Adler H. S., Mischak H., Janosch P., Heidecker G., Wolfman A., Pippig S., Lohse M., Ueffing M., Kolch W. Mechanism of inhibition of Raf-1 by protein kinase A. Mol Cell Biol. 1994 Oct;14(10):6696–6703. doi: 10.1128/mcb.14.10.6696. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Jaiswal R. K., Weissinger E., Kolch W., Landreth G. E. Nerve growth factor-mediated activation of the mitogen-activated protein (MAP) kinase cascade involves a signaling complex containing B-Raf and HSP90. J Biol Chem. 1996 Sep 27;271(39):23626–23629. doi: 10.1074/jbc.271.39.23626. [DOI] [PubMed] [Google Scholar]
  42. Jelinek T., Dent P., Sturgill T. W., Weber M. J. Ras-induced activation of Raf-1 is dependent on tyrosine phosphorylation. Mol Cell Biol. 1996 Mar;16(3):1027–1034. doi: 10.1128/mcb.16.3.1027. [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Johnson G. L., Gardner A. M., Lange-Carter C., Qian N. X., Russell M., Winitz S. How does the G protein, Gi2, transduce mitogenic signals? J Cell Biochem. 1994 Apr;54(4):415–422. doi: 10.1002/jcb.240540408. [DOI] [PubMed] [Google Scholar]
  44. Kabarowski J. H., Allen P. B., Wiedemann L. M. A temperature sensitive p210 BCR-ABL mutant defines the primary consequences of BCR-ABL tyrosine kinase expression in growth factor dependent cells. EMBO J. 1994 Dec 15;13(24):5887–5895. doi: 10.1002/j.1460-2075.1994.tb06934.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. Kan O., Baldwin S. A., Whetton A. D. Apoptosis is regulated by the rate of glucose transport in an interleukin 3 dependent cell line. J Exp Med. 1994 Sep 1;180(3):917–923. doi: 10.1084/jem.180.3.917. [DOI] [PMC free article] [PubMed] [Google Scholar]
  46. Karnitz L. M., Burns L. A., Sutor S. L., Blenis J., Abraham R. T. Interleukin-2 triggers a novel phosphatidylinositol 3-kinase-dependent MEK activation pathway. Mol Cell Biol. 1995 Jun;15(6):3049–3057. doi: 10.1128/mcb.15.6.3049. [DOI] [PMC free article] [PubMed] [Google Scholar]
  47. Kato J. Y., Matsuoka M., Polyak K., Massagué J., Sherr C. J. Cyclic AMP-induced G1 phase arrest mediated by an inhibitor (p27Kip1) of cyclin-dependent kinase 4 activation. Cell. 1994 Nov 4;79(3):487–496. doi: 10.1016/0092-8674(94)90257-7. [DOI] [PubMed] [Google Scholar]
  48. Kauffmann-Zeh A., Rodriguez-Viciana P., Ulrich E., Gilbert C., Coffer P., Downward J., Evan G. Suppression of c-Myc-induced apoptosis by Ras signalling through PI(3)K and PKB. Nature. 1997 Feb 6;385(6616):544–548. doi: 10.1038/385544a0. [DOI] [PubMed] [Google Scholar]
  49. Kizaka-Kondoh S., Okayama H. Raf-1 is not a major upstream regulator of MAP kinases in rat fibroblasts. FEBS Lett. 1993 Dec 27;336(2):255–258. doi: 10.1016/0014-5793(93)80814-b. [DOI] [PubMed] [Google Scholar]
  50. Kolch W., Heidecker G., Kochs G., Hummel R., Vahidi H., Mischak H., Finkenzeller G., Marmé D., Rapp U. R. Protein kinase C alpha activates RAF-1 by direct phosphorylation. Nature. 1993 Jul 15;364(6434):249–252. doi: 10.1038/364249a0. [DOI] [PubMed] [Google Scholar]
  51. Kolch W., Heidecker G., Troppmair J., Yanagihara K., Bassin R. H., Rapp U. R. Raf revertant cells resist transformation by non-nuclear oncogenes and are deficient in the induction of early response genes by TPA and serum. Oncogene. 1993 Feb;8(2):361–370. [PubMed] [Google Scholar]
  52. Kortenjann M., Thomae O., Shaw P. E. Inhibition of v-raf-dependent c-fos expression and transformation by a kinase-defective mutant of the mitogen-activated protein kinase Erk2. Mol Cell Biol. 1994 Jul;14(7):4815–4824. doi: 10.1128/mcb.14.7.4815. [DOI] [PMC free article] [PubMed] [Google Scholar]
  53. Krautwald S., Büscher D., Dent P., Ruthenberg K., Baccarini M. Suppression of growth factor-mediated MAP kinase activation by v-raf in macrophages: a putative role for the MKP-1 phosphatase. Oncogene. 1995 Mar 16;10(6):1187–1192. [PubMed] [Google Scholar]
  54. Kurzrock R., Gutterman J. U., Talpaz M. The molecular genetics of Philadelphia chromosome-positive leukemias. N Engl J Med. 1988 Oct 13;319(15):990–998. doi: 10.1056/NEJM198810133191506. [DOI] [PubMed] [Google Scholar]
  55. Largaespada D. A., Kaehler D. A., Mishak H., Weissinger E., Potter M., Mushinski J. F., Risser R. A retrovirus that expresses v-abl and c-myc oncogenes rapidly induces plasmacytomas. Oncogene. 1992 Apr;7(4):811–819. [PubMed] [Google Scholar]
  56. Leevers S. J., Paterson H. F., Marshall C. J. Requirement for Ras in Raf activation is overcome by targeting Raf to the plasma membrane. Nature. 1994 Jun 2;369(6479):411–414. doi: 10.1038/369411a0. [DOI] [PubMed] [Google Scholar]
  57. Lovrić J., Moelling K. Activation of Mil/Raf protein kinases in mitotic cells. Oncogene. 1996 Mar 7;12(5):1109–1116. [PubMed] [Google Scholar]
  58. Marais R., Light Y., Paterson H. F., Marshall C. J. Ras recruits Raf-1 to the plasma membrane for activation by tyrosine phosphorylation. EMBO J. 1995 Jul 3;14(13):3136–3145. doi: 10.1002/j.1460-2075.1995.tb07316.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  59. Marshall C. J. MAP kinase kinase kinase, MAP kinase kinase and MAP kinase. Curr Opin Genet Dev. 1994 Feb;4(1):82–89. doi: 10.1016/0959-437x(94)90095-7. [DOI] [PubMed] [Google Scholar]
  60. Matsuda M., Hashimoto Y., Muroya K., Hasegawa H., Kurata T., Tanaka S., Nakamura S., Hattori S. CRK protein binds to two guanine nucleotide-releasing proteins for the Ras family and modulates nerve growth factor-induced activation of Ras in PC12 cells. Mol Cell Biol. 1994 Aug;14(8):5495–5500. doi: 10.1128/mcb.14.8.5495. [DOI] [PMC free article] [PubMed] [Google Scholar]
  61. McCormick F. Signal transduction. How receptors turn Ras on. Nature. 1993 May 6;363(6424):15–16. doi: 10.1038/363015a0. [DOI] [PubMed] [Google Scholar]
  62. Miller A. D., Miller D. G., Garcia J. V., Lynch C. M. Use of retroviral vectors for gene transfer and expression. Methods Enzymol. 1993;217:581–599. doi: 10.1016/0076-6879(93)17090-r. [DOI] [PubMed] [Google Scholar]
  63. Mischak H., Seitz T., Janosch P., Eulitz M., Steen H., Schellerer M., Philipp A., Kolch W. Negative regulation of Raf-1 by phosphorylation of serine 621. Mol Cell Biol. 1996 Oct;16(10):5409–5418. doi: 10.1128/mcb.16.10.5409. [DOI] [PMC free article] [PubMed] [Google Scholar]
  64. Mitra G., Weber M., Stacey D. Multiple pathways for activation of MAP kinases. Cell Mol Biol Res. 1993;39(5):517–523. [PubMed] [Google Scholar]
  65. Moodie S. A., Paris M., Villafranca E., Kirshmeier P., Willumsen B. M., Wolfman A. Different structural requirements within the switch II region of the Ras protein for interactions with specific downstream targets. Oncogene. 1995 Aug 3;11(3):447–454. [PubMed] [Google Scholar]
  66. Moodie S. A., Wolfman A. The 3Rs of life: Ras, Raf and growth regulation. Trends Genet. 1994 Feb;10(2):44–48. doi: 10.1016/0168-9525(94)90147-3. [DOI] [PubMed] [Google Scholar]
  67. Owen-Lynch P. J., Wong A. K., Whetton A. D. v-Abl-mediated apoptotic suppression is associated with SHC phosphorylation without concomitant mitogen-activated protein kinase activation. J Biol Chem. 1995 Mar 17;270(11):5956–5962. doi: 10.1074/jbc.270.11.5956. [DOI] [PubMed] [Google Scholar]
  68. Pendergast A. M., Quilliam L. A., Cripe L. D., Bassing C. H., Dai Z., Li N., Batzer A., Rabun K. M., Der C. J., Schlessinger J. BCR-ABL-induced oncogenesis is mediated by direct interaction with the SH2 domain of the GRB-2 adaptor protein. Cell. 1993 Oct 8;75(1):175–185. [PubMed] [Google Scholar]
  69. Prouty S. M., Hanson K. D., Boyle A. L., Brown J. R., Shichiri M., Follansbee M. R., Kang W., Sedivy J. M. A cell culture model system for genetic analyses of the cell cycle by targeted homologous recombination. Oncogene. 1993 Apr;8(4):899–907. [PubMed] [Google Scholar]
  70. Rapp U. R., Cleveland J. L., Storm S. M., Beck T. W., Huleihel M. Transformation by raf and myc oncogenes. Princess Takamatsu Symp. 1986;17:55–74. [PubMed] [Google Scholar]
  71. Rapp U. R., Troppmair J., Beck T., Birrer M. J. Transformation by Raf and other oncogenes renders cells differentially sensitive to growth inhibition by a dominant negative c-jun mutant. Oncogene. 1994 Dec;9(12):3493–3498. [PubMed] [Google Scholar]
  72. Ren R., Ye Z. S., Baltimore D. Abl protein-tyrosine kinase selects the Crk adapter as a substrate using SH3-binding sites. Genes Dev. 1994 Apr 1;8(7):783–795. doi: 10.1101/gad.8.7.783. [DOI] [PubMed] [Google Scholar]
  73. Renshaw M. W., Kipreos E. T., Albrecht M. R., Wang J. Y. Oncogenic v-Abl tyrosine kinase can inhibit or stimulate growth, depending on the cell context. EMBO J. 1992 Nov;11(11):3941–3951. doi: 10.1002/j.1460-2075.1992.tb05488.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  74. Renshaw M. W., McWhirter J. R., Wang J. Y. The human leukemia oncogene bcr-abl abrogates the anchorage requirement but not the growth factor requirement for proliferation. Mol Cell Biol. 1995 Mar;15(3):1286–1293. doi: 10.1128/mcb.15.3.1286. [DOI] [PMC free article] [PubMed] [Google Scholar]
  75. Reuter C. W., Catling A. D., Jelinek T., Weber M. J. Biochemical analysis of MEK activation in NIH3T3 fibroblasts. Identification of B-Raf and other activators. J Biol Chem. 1995 Mar 31;270(13):7644–7655. doi: 10.1074/jbc.270.13.7644. [DOI] [PubMed] [Google Scholar]
  76. Roche S., Fumagalli S., Courtneidge S. A. Requirement for Src family protein tyrosine kinases in G2 for fibroblast cell division. Science. 1995 Sep 15;269(5230):1567–1569. doi: 10.1126/science.7545311. [DOI] [PubMed] [Google Scholar]
  77. Rosenberg N., Witte O. N. The viral and cellular forms of the Abelson (abl) oncogene. Adv Virus Res. 1988;35:39–81. doi: 10.1016/s0065-3527(08)60708-3. [DOI] [PubMed] [Google Scholar]
  78. Russell M., Winitz S., Johnson G. L. Acetylcholine muscarinic m1 receptor regulation of cyclic AMP synthesis controls growth factor stimulation of Raf activity. Mol Cell Biol. 1994 Apr;14(4):2343–2351. doi: 10.1128/mcb.14.4.2343. [DOI] [PMC free article] [PubMed] [Google Scholar]
  79. Sattler M., Salgia R., Okuda K., Uemura N., Durstin M. A., Pisick E., Xu G., Li J. L., Prasad K. V., Griffin J. D. The proto-oncogene product p120CBL and the adaptor proteins CRKL and c-CRK link c-ABL, p190BCR/ABL and p210BCR/ABL to the phosphatidylinositol-3' kinase pathway. Oncogene. 1996 Feb 15;12(4):839–846. [PubMed] [Google Scholar]
  80. Sawyers C. L., Callahan W., Witte O. N. Dominant negative MYC blocks transformation by ABL oncogenes. Cell. 1992 Sep 18;70(6):901–910. doi: 10.1016/0092-8674(92)90241-4. [DOI] [PubMed] [Google Scholar]
  81. Sawyers C. L., McLaughlin J., Witte O. N. Genetic requirement for Ras in the transformation of fibroblasts and hematopoietic cells by the Bcr-Abl oncogene. J Exp Med. 1995 Jan 1;181(1):307–313. doi: 10.1084/jem.181.1.307. [DOI] [PMC free article] [PubMed] [Google Scholar]
  82. Sawyers C. L. The role of myc in transformation by BCR-ABL. Leuk Lymphoma. 1993;11 (Suppl 1):45–46. doi: 10.3109/10428199309047862. [DOI] [PubMed] [Google Scholar]
  83. Seth A., Gupta S., Davis R. J. Cell cycle regulation of the c-Myc transcriptional activation domain. Mol Cell Biol. 1993 Jul;13(7):4125–4136. doi: 10.1128/mcb.13.7.4125. [DOI] [PMC free article] [PubMed] [Google Scholar]
  84. Sevetson B. R., Kong X., Lawrence J. C., Jr Increasing cAMP attenuates activation of mitogen-activated protein kinase. Proc Natl Acad Sci U S A. 1993 Nov 1;90(21):10305–10309. doi: 10.1073/pnas.90.21.10305. [DOI] [PMC free article] [PubMed] [Google Scholar]
  85. Sherr C. J., Roberts J. M. Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev. 1995 May 15;9(10):1149–1163. doi: 10.1101/gad.9.10.1149. [DOI] [PubMed] [Google Scholar]
  86. Stanton L. W., Watt R., Marcu K. B. Translocation, breakage and truncated transcripts of c-myc oncogene in murine plasmacytomas. Nature. 1983 Jun 2;303(5916):401–406. doi: 10.1038/303401a0. [DOI] [PubMed] [Google Scholar]
  87. Stokoe D., Macdonald S. G., Cadwallader K., Symons M., Hancock J. F. Activation of Raf as a result of recruitment to the plasma membrane. Science. 1994 Jun 3;264(5164):1463–1467. doi: 10.1126/science.7811320. [DOI] [PubMed] [Google Scholar]
  88. Sun X. M., Snowden R. T., Skilleter D. N., Dinsdale D., Ormerod M. G., Cohen G. M. A flow-cytometric method for the separation and quantitation of normal and apoptotic thymocytes. Anal Biochem. 1992 Aug 1;204(2):351–356. doi: 10.1016/0003-2697(92)90251-2. [DOI] [PubMed] [Google Scholar]
  89. Sözeri O., Vollmer K., Liyanage M., Frith D., Kour G., Mark G. E., 3rd, Stabel S. Activation of the c-Raf protein kinase by protein kinase C phosphorylation. Oncogene. 1992 Nov;7(11):2259–2262. [PubMed] [Google Scholar]
  90. Tauchi T., Broxmeyer H. E. BCR/ABL signal transduction. Int J Hematol. 1995 Apr;61(3):105–112. doi: 10.1016/0925-5710(95)00361-u. [DOI] [PubMed] [Google Scholar]
  91. Taylor S. J., Shalloway D. An RNA-binding protein associated with Src through its SH2 and SH3 domains in mitosis. Nature. 1994 Apr 28;368(6474):867–871. doi: 10.1038/368867a0. [DOI] [PubMed] [Google Scholar]
  92. Thompson P. A., Ledbetter J. A., Rapp U. R., Bolen J. B. The Raf-1 serine-threonine kinase is a substrate for the p56lck protein tyrosine kinase in human T-cells. Cell Growth Differ. 1991 Dec;2(12):609–617. [PubMed] [Google Scholar]
  93. Troppmair J., Bruder J. T., Munoz H., Lloyd P. A., Kyriakis J., Banerjee P., Avruch J., Rapp U. R. Mitogen-activated protein kinase/extracellular signal-regulated protein kinase activation by oncogenes, serum, and 12-O-tetradecanoylphorbol-13-acetate requires Raf and is necessary for transformation. J Biol Chem. 1994 Mar 4;269(9):7030–7035. [PubMed] [Google Scholar]
  94. Varticovski L., Daley G. Q., Jackson P., Baltimore D., Cantley L. C. Activation of phosphatidylinositol 3-kinase in cells expressing abl oncogene variants. Mol Cell Biol. 1991 Feb;11(2):1107–1113. doi: 10.1128/mcb.11.2.1107. [DOI] [PMC free article] [PubMed] [Google Scholar]
  95. Wang H. G., Rapp U. R., Reed J. C. Bcl-2 targets the protein kinase Raf-1 to mitochondria. Cell. 1996 Nov 15;87(4):629–638. doi: 10.1016/s0092-8674(00)81383-5. [DOI] [PubMed] [Google Scholar]
  96. Williams N. G., Roberts T. M., Li P. Both p21ras and pp60v-src are required, but neither alone is sufficient, to activate the Raf-1 kinase. Proc Natl Acad Sci U S A. 1992 Apr 1;89(7):2922–2926. doi: 10.1073/pnas.89.7.2922. [DOI] [PMC free article] [PubMed] [Google Scholar]
  97. Williams N. G., Roberts T. M. Signal transduction pathways involving the Raf proto-oncogene. Cancer Metastasis Rev. 1994 Mar;13(1):105–116. doi: 10.1007/BF00690421. [DOI] [PubMed] [Google Scholar]
  98. Wong K. K., Zou X., Merrell K. T., Patel A. J., Marcu K. B., Chellappan S., Calame K. v-Abl activates c-myc transcription through the E2F site. Mol Cell Biol. 1995 Dec;15(12):6535–6544. doi: 10.1128/mcb.15.12.6535. [DOI] [PMC free article] [PubMed] [Google Scholar]
  99. Wu J., Dent P., Jelinek T., Wolfman A., Weber M. J., Sturgill T. W. Inhibition of the EGF-activated MAP kinase signaling pathway by adenosine 3',5'-monophosphate. Science. 1993 Nov 12;262(5136):1065–1069. doi: 10.1126/science.7694366. [DOI] [PubMed] [Google Scholar]
  100. Zha J., Harada H., Yang E., Jockel J., Korsmeyer S. J. Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14-3-3 not BCL-X(L) Cell. 1996 Nov 15;87(4):619–628. doi: 10.1016/s0092-8674(00)81382-3. [DOI] [PubMed] [Google Scholar]

Articles from Molecular and Cellular Biology are provided here courtesy of Taylor & Francis

RESOURCES